-
Carboplatin at the Metabolism–DNA Damage Interface
2026-10-01
Carboplatin is more than a conventional cytotoxic control: it can serve as a translational probe connecting DNA synthesis failure with the metabolic states that sustain tumor growth. This article examines how CIP2A-driven oxidative phosphorylation in non-small cell lung cancer may inform Carboplatin study design while separating established evidence from testable hypotheses.
-
FXYD5 Downregulation and Cisplatin Resistance in EOC
2026-10-01
The reference study identifies FXYD5 as a functional contributor to cisplatin resistance in epithelial ovarian cancer cell models. Its findings connect FXYD5 depletion with lower drug-response IC50 values, reduced epithelial–mesenchymal transition features, impaired motility, decreased proliferation, and increased apoptosis, while also illustrating how MTT-based metabolic measurements can be integrated with orthogonal cellular assays.
-
Brush Polymer Lipids for Repeat-Dose mRNA LNPs
2026-09-30
This Nature Materials study introduces high-density brush-shaped polymer lipids as alternatives to conventional PEG lipids in mRNA lipid nanoparticles. By reducing anti-PEG antibody binding while preserving or improving delivery, the approach supports more consistent repeat-dose protein replacement and genome editing in preclinical models.
-
Losartan in Podocyte–Vascular Research
2026-09-30
Explore how Losartan can serve as a mechanistic AT1-receptor probe across vascular and renal research. This article translates recent FGF4–FGFR1 findings into practical assay-design decisions without conflating angiotensin signaling with podocyte-specific protection.
-
Polygodial for TRPA1 Assay Workflows
2026-09-29
Build reproducible TRPA1 activation assays with Polygodial while separating acute calcium flux from delayed epithelial inflammatory signaling. This workflow translates TRPA1–Ca2+–NFAT findings into practical controls for ion channel, sensory biology, and neurophysiology research.
-
AZ505 SMYD2 Inhibitor: Workflow & Applications
2026-09-29
AZ505 supports mechanism-first studies of SMYD2-dependent methylation, from peptide-substrate biochemical assays to cisplatin-associated renal fibrosis models. Its substrate-competitive profile and reported selectivity make it useful for epigenetic regulation research, while careful controls are essential when extending findings to cancer biology.
-
Schizophrenia Risk Pathways in Developing Neurons
2026-09-28
Liu et al. show that schizophrenia-associated genetic signals converge on different molecular pathways in developing cortical interneurons and glutamatergic neurons. Their cell-type-resolved iPSC experiments connect interneuron risk-gene dysregulation to PKC hyperactivity and arborization deficits, while linking glutamatergic-neuron pathway disruption to impaired calcium currents.
-
Phosbind Biotin for Phosphorylation Analysis
2026-09-27
Phosbind Biotin detects phosphorylated proteins on PVDF membranes through dinuclear metal complex phosphate binding, without requiring a sequence-specific phospho-antibody. Its use in Western Blot detection of phosphorylated proteins complements biological studies of phosphorylation, including recent work on salt signaling in rice.
-
Berberrubine chloride: Reliable Cell Assay Design
2026-09-26
A scenario-driven guide to using Berberrubine chloride (SKU N2089) in viability, proliferation, and cytotoxicity workflows. It explains solvent handling, concentration selection, mechanistic interpretation, and practical criteria for choosing a research-grade source without overstating the evidence.
-
DiscoveryProbe Stem Cell Compound Library Plus Workflow
2026-09-26
Turn a 280-compound, pathway-focused collection into a practical screening plan that links quantitative phenotypes with mechanism-aware follow-up. A high-content schistosome study illustrates how stem-cell-focused perturbations can reveal effects missed by morphology alone—while also clarifying the limits of carrying results across biological systems.
-
Azilsartan in RAS and Reactive Astrocyte Research
2026-09-25
Use Azilsartan (TAK-536) to isolate AT1-receptor contributions in renin–angiotensin system assays, including microglia-to-astrocyte inflammation models. This guide translates a 2024 study into a controllable workflow, with practical dosing, vehicle, and interpretation checks.
-
SB525334 for TGF-β1 Pathway Experiments
2026-09-25
Use SB525334 to test whether ALK5–Smad2/3 signaling drives profibrotic outputs—or contributes to repair—in your model. New bone-transport findings make timing and tissue context especially important: blocking TGF-β1 signaling can clarify mechanism, but may also blunt beneficial wound-healing responses.
-
Azithromycin and Roxithromycin as Senolytic Candidates
2026-09-24
A 2018 study used DNA-damage-induced senescence in human fibroblasts to identify azithromycin and roxithromycin as candidate senolytic drugs, while the related macrolide erythromycin was inactive in the tested assays. The results offer a screening framework and metabolic clues, but remain preclinical cell-culture findings; they do not establish senolytic activity for Azathramycin A or clinical benefit.
-
Nicotine Signaling in Smoking-Related CKD Progression
2026-09-24
Jain and Jaimes review clinical and experimental evidence linking cigarette smoking—and nicotine in particular—to worsening chronic kidney disease (CKD). Their synthesis highlights nicotinic acetylcholine receptor signaling, oxidative stress, and pro-fibrotic responses as candidate mechanisms, while identifying important limits in separating nicotine’s effects from those of whole cigarette smoke.
-
SMAD3 Inhibition and ADAMTS-5 in Early OA
2026-09-23
Xiang et al. show that inhibiting SMAD3 with SIS3 reduces ADAMTS-5 expression in inflammatory chondrocytes and in a rat model of early osteoarthritis. The findings support a regulatory connection between SMAD3, miRNA-140, and cartilage catabolism, while also emphasizing that pathway effects are most evident before major structural damage develops.